# CorMedix Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/CorMedix Inc.). ## Overview CorMedix Inc. is a U.S.-based biopharmaceutical company that develops and commercializes therapies for serious, life-threatening conditions. Its core commercial product is DefenCath, an antimicrobial catheter lock solution used in hemodialysis patients, and in 2025 the company expanded through the acquisition of Melinta Therapeutics, adding a hospital-focused infectious disease portfolio and a cardiovascular brand. ## Products & services • DefenCath® catheter lock solution for hemodialysis patients • REZZAYO® antifungal for invasive Candida infections • MINOCIN® IV injectable minocycline • VABOMERE® antibacterial for complicated infections • KIMYRSA®, ORBACTIV®, and BAXDELA® anti-infectives • TOPROL-XL® extended-release metoprolol succinate - **DefenCath** (55%) — Commercial antimicrobial catheter lock solution sold in the U.S. dialysis market to reduce catheter-related bloodstream infections. - **Melinta infectious disease portfolio** (35%) — Hospital- and clinic-focused anti-infective products used for gram-positive, gram-negative, and fungal infections. - **TOPROL-XL** (5%) — Branded cardiovascular product with mature, limited-demand sales in a highly genericized beta-blocker class. - **Contract and collaboration revenue** (5%) — BARDA and other licensing, milestone, royalty, and R&D service revenue tied to partnered programs. - DefenCath® antimicrobial catheter lock solution for dialysis patients - REZZAYO® (rezafungin) for serious fungal infections - MINOCIN® IV, VABOMERE®, KIMYRSA®, ORBACTIV®, and BAXDELA® - TOPROL-XL® branded cardiovascular therapy - BARDA-funded pediatric and biothreat development programs ## Customers CorMedix sells primarily to U.S. dialysis organizations, outpatient service providers, specialty distributors, and hospital-system buyers that manage infection prevention and acute care treatment pathways. After the Melinta acquisition, its customer base also includes hospitals, emergency departments, outpatient clinics, and home infusion channels that purchase anti-infectives for serious infections. - **Dialysis organizations** (primary) — Buy DefenCath to reduce catheter-related bloodstream infections in chronic hemodialysis patients. - **Hospital and acute care providers** (primary) — Buy Melinta anti-infectives for inpatient and hospital-ecosystem treatment of serious infections. - **Specialty distributors** (secondary) — Distribute product into outpatient and hospital channels and support access to end customers. - **Government and public health agencies** (secondary) — Fund BARDA-supported development programs for pediatric and biothreat indications. - **Cardiovascular prescribers and pharmacies** (secondary) — Purchase TOPROL-XL where branded demand persists despite generic competition. - Large dialysis organizations buying DefenCath for outpatient hemodialysis centers - Outpatient service providers and specialty distributors in the U.S. - Hospitals and hospital ecosystems purchasing anti-infectives - Emergency departments, clinics, and home infusion providers - Government and BARDA counterparties funding development work ## Geography CorMedix is primarily a U.S. business, with DefenCath commercialized in the United States and most customers located domestically. The Melinta acquisition adds U.S. hospital and clinic channels, while partnered licensing and BARDA-related activities extend some revenue exposure beyond pure product sales through collaboration and territory-based arrangements. - United States is the core commercial market for DefenCath and Melinta products - U.S. dialysis centers are the main access point for DefenCath adoption - Hospital, clinic, and home infusion channels are concentrated in the U.S. - BARDA and licensing arrangements create non-product revenue exposure - Foreign supplier reliance creates import and logistics exposure even if sales are U.S.-centric ## Strategy CorMedix’s strategy is to maximize the value of its commercial portfolio by scaling DefenCath and using the Melinta platform to broaden hospital access and cross-selling opportunities. It is also pursuing label expansions for DefenCath and REZZAYO, while using business development to add assets that fit its sales infrastructure and support longer-term growth. - **Scale DefenCath commercialization** (short-term) — DefenCath is the largest contributor to net sales and the core growth driver. - **Integrate and monetize the Melinta portfolio** (short-term) — The acquisition adds marketed products and a hospital-focused commercial platform. - **Pursue label expansions** (medium-term) — Additional indications can extend product lifecycles and broaden reimbursement access. - **Add synergistic assets through business development** (medium-term) — New products can improve commercial leverage and reduce dependence on one asset. - Expand DefenCath penetration in dialysis and related care settings - Use Melinta's hospital platform to broaden commercial reach - Pursue expanded indications for DefenCath and REZZAYO - Leverage multi-channel anti-infective portfolio synergies - Seek synergistic business development opportunities ## Risks CorMedix is exposed to customer concentration, reimbursement changes, and dependence on third-party manufacturers, all of which can quickly affect revenue and margins. The company also faces typical biopharma risks around clinical development, regulatory approvals, competition, and supply chain reliability, with added sensitivity to cybersecurity and data/privacy compliance because operations rely on external vendors and digital systems. - **Customer concentration** [high] — A few customers account for a large share of revenue and can change purchasing with little notice. - **Reimbursement and pricing pressure** [high] — DefenCath economics depend on dialysis reimbursement dynamics and payer acceptance. - **Third-party manufacturing dependence** [high] — The company outsources all manufacturing and relies on single-source suppliers for some inputs. - **Clinical and regulatory execution** [medium] — Expanded indications require successful trials, filings, and FDA review. - **Cybersecurity and third-party vendor disruption** [medium] — Operations depend on cloud, CRO, CMO, logistics, and analytics vendors. - Top customers account for most revenue, creating concentration risk - DefenCath reimbursement changes could reduce adoption and pricing - Third-party manufacturing and single-source supply can cause delays - Clinical and regulatory outcomes for new indications are uncertain - Cybersecurity or vendor outages could disrupt operations and supply ## Accounting Revenue recognition is a key judgment area because product sales are recorded net of chargebacks, discounts, rebates, returns, shelf-stock adjustments, and data fees, and the company is still building historical experience for DefenCath. The Melinta acquisition also adds contract revenue, royalties, and intangible asset amortization, while acquired product intangibles and return reserves can materially affect reported margins and earnings. - **Revenue recognition and variable consideration** — Can materially shift reported revenue and gross margin as estimates are updated. - **Returns reserve** — Affects net sales and accrual balances; accrued returns were significant in 2025. - **Intangible asset amortization** — Raises cost of revenues and depresses operating profitability. - **Acquisition accounting** — Can affect future amortization, goodwill, and impairment risk. - **Lease accounting** — Affects operating lease expense and balance sheet obligations. - Net product revenue depends on estimates for rebates, returns, and chargebacks - DefenCath has limited historical sales data, increasing estimate volatility - Melinta adds contract, royalty, and milestone revenue streams - Acquired intangible assets create amortization expense in cost of revenues - Lease and contingent liability disclosures affect operating expense and obligations --- *Last updated: 2026-04-28T19:59:10.147812+00:00*